Stonepine Capital Management’s Ovid Therapeutics OVID Stock Holding History

Stonepine Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.3K	Sell	21,300 -18,700	-47%	-$48.3K	0.03%	86
2026 Q1	$88.8K	Sell	40,000 -62,367	-61%	-$112K	0.04%	80
2025 Q4	$167K	Buy	+102,367	New	+$158K	0.12%	61
2022 Q4	–	Sell	-1,540,671	Closed	-$2.83M	–	23
2022 Q3	$2.83M	Sell	1,540,671 -1,947,257	-56%	-$4.07M	1.27%	15
2022 Q2	$7.5M	Sell	3,487,928 -730,141	-17%	-$1.76M	3.49%	13
2022 Q1	$13.2M	Buy	4,218,069 +211,884	+5%	+$667K	5.49%	5
2021 Q4	$12.9M	Buy	4,006,185 +753,293	+23%	+$2.58M	5.9%	5
2021 Q3	$10.9M	Buy	3,252,892 +1,252,892	+63%	+$4.57M	4.97%	5
2021 Q2	$7.82M	Sell	2,000,000 -483,059	-19%	-$1.91M	4.09%	7
2021 Q1	$9.98M	Buy	+2,483,059	New	+$8.25M	5.39%	6

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Stonepine Capital Management's OVID Position: Q2 2026 in Review

Stonepine Capital Management reduced its Ovid Therapeutics (OVID) stake by 47% in Q2 2026, selling an estimated $48.3K and leaving 21,300 shares worth $57.3K. The position accounts for 0.03% of the portfolio, ranked #86.

Stonepine Capital Management first reported a position in OVID in Q1 2021 and has held it in 10 quarters since. The position peaked at $13.2M in Q1 2022. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Stonepine Capital Management held 21,300 shares of Ovid Therapeutics worth $57.3K as of Q2 2026.
Stonepine Capital Management sold 18,700 Ovid Therapeutics shares in Q2 2026, an estimated $48.3K.
Ovid Therapeutics made up 0.03% of Stonepine Capital Management's portfolio in Q2 2026, its #86 holding.
Stonepine Capital Management first reported a position in Ovid Therapeutics in Q1 2021 and has held it in 10 quarters since.
Stonepine Capital Management's Ovid Therapeutics position peaked at $13.2M in Q1 2022.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.